Description

Etopozid-TEVA (Etoposide) Concentrate for Infusions 20 mg/ml – 10 ml – №1 Vial

Ingredients:

Each milliliter contains 20 mg of etoposide as the active ingredient.

Mechanism of Action:

Etopozid-TEVA exerts its pharmacological effects by inhibiting topoisomerase II, an enzyme crucial for DNA replication in cancer cells. This inhibition leads to cell death and contributes to tumor regression.

Pharmacological Properties:

Etoposide, the active component of Etopozid-TEVA, demonstrates potent antineoplastic activity by interfering with DNA synthesis in rapidly dividing cancer cells.

Indications for Use:

Etopozid-TEVA is indicated for the treatment of various cancers, including lung cancer, testicular cancer, and lymphomas, by impeding cancer cell growth and proliferation.

Contraindications:

Avoid using Etopozid-TEVA if there is a known hypersensitivity to etoposide or any other constituents of the product. Prior medical conditions and ongoing medications should be discussed with a healthcare provider before initiating treatment.

Side Effects:

Common side effects of Etopozid-TEVA may include nausea, vomiting, myelosuppression, and alopecia. Monitoring for adverse reactions during treatment is essential.

Usage Instructions:

Etopozid-TEVA should be administered intravenously by experienced healthcare professionals specializing in cancer chemotherapy. The infusion rate should be controlled to minimize potential side effects.

Benefits Compared to Analogues:

Etopozid-TEVA offers a targeted therapeutic approach to cancer treatment with a well-documented safety and efficacy profile, distinguishing it as a preferred option in oncology.

Suitable Patient Groups:

Etopozid-TEVA is suitable for adults and may be used in specific pediatric cases under healthcare provider supervision. Dosage adjustments may be necessary for elderly patients.

Storage Conditions and Shelf Life:

Etopozid-TEVA should be stored as per the manufacturer’s instructions, away from light and moisture. Check the expiration date on the packaging and do not use expired products.

Packaging Description:

Etopozid-TEVA is available in 10 ml vials as a concentrate for infusion, providing a convenient and sterile dosage form for administration.

Clinical Evidence and Proven Effectiveness:

Etoposide, the key component of Etopozid-TEVA, has shown significant efficacy in inhibiting cancer cell growth via topoisomerase II inhibition. Clinical trials have demonstrated the antitumor activity and tolerability of Etopozid-TEVA in cancer patients.